Literature DB >> 1968452

Skeletal muscle tremor and the influence of adrenergic drugs.

R C Ahrens1.   

Abstract

Physiologic postural skeletal muscle tremor is enhanced by beta 2 receptor agonist such as those used in the treatment of asthma. This is a peripheral response rather than one occurring at the central nervous system level. It is greatest when drugs are administered by the oral or parenteral routes, and is the most important dose-limiting factor for oral administration. Clinically important tremor is minimal after aerosolized administration of clinically recommended doses of aerosolized beta 2 receptor agonists, but can be significant when larger doses are administered. Sympathomimetic drugs which can selectively stimulate airway beta 2 receptors, as opposed to skeletal muscle beta 2 receptors, do not currently exist. Combining orally administered beta 2 agents with theophylline potentiates the effects on muscle tremor. There does not seem to be a clinical advantage, in terms of reduced side effects such as muscle tremor, to combining "small doses" of oral beta agonists and theophylline as opposed to using either agent alone in optimal doses. Tolerance to the tremoregenic effects of beta 2 agonists appears to occur when these agents are administered on a chronic basis. Thus, there may be some rationale for beginning oral beta agonists initially with lower doses and progressively increasing to full doses over a period of days to weeks.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1968452     DOI: 10.3109/02770909009073289

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  8 in total

1.  Chronic asthma.

Authors:  C Cates
Journal:  BMJ       Date:  2001-10-27

Review 2.  Asthma in adults.

Authors:  Rodolfo J Dennis; Ivan Solarte; Gustavo Rodrigo
Journal:  BMJ Clin Evid       Date:  2011-07-13

Review 3.  Asthma in adults.

Authors:  Rodolfo J Dennis; Ivan Solarte; Gustavo Rodrigo
Journal:  BMJ Clin Evid       Date:  2010-01-21

4.  Pharmacokinetics of bambuterol in healthy subjects.

Authors:  L Nyberg; J Rosenborg; E Weibull; S Jönsson; B M Kennedy; M Nilsson
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

5.  Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma. ACROBATICS Research Group.

Authors:  S D Gunn; J G Ayres; S M McConchie
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 6.  Insights into Pathophysiology from Medication-induced Tremor.

Authors:  John C Morgan; Julie A Kurek; Jennie L Davis; Kapil D Sethi
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2017-11-22

Review 7.  Use of ICS/LABA (extra-fine and non-extra-fine) in elderly asthmatics.

Authors:  Alida Benfante; Marco Basile; Salvatore Battaglia; Mario Spatafora; Nicola Scichilone
Journal:  Ther Clin Risk Manag       Date:  2016-10-14       Impact factor: 2.423

8.  Sarcomeric deficits underlie MYBPC1-associated myopathy with myogenic tremor.

Authors:  Janelle Geist Hauserman; Janis Stavusis; Humberto C Joca; Joel C Robinett; Laurin Hanft; Jack Vandermeulen; Runchen Zhao; Joseph P Stains; Konstantinos Konstantopoulos; Kerry S McDonald; Christopher Ward; Aikaterini Kontrogianni-Konstantopoulos
Journal:  JCI Insight       Date:  2021-10-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.